Oncogenic Mutations and Tumor Microenvironment Alterations of Older Patients With Diffuse Large B-Cell Lymphoma

Front Immunol. 2022 Mar 25;13:842439. doi: 10.3389/fimmu.2022.842439. eCollection 2022.


The incidence of diffuse large B-cell lymphoma (DLBCL) increases by age and older DLBCL are commonly related to poor prognosis. However, the clinical and biological features of older DLBCL patients remain to be determined. A total of 2,445 patients with newly diagnosed DLBCL were enrolled for clinical data analysis according to age at diagnosis, with tumor samples of 1,150 patients assessed by DNA sequencing and 385 patients by RNA sequencing. Older DLBCL presented advanced disease stage, elevated serum lactate dehydrogenase, poor performance status, multiple extranodal involvement, high percentage of double expressor subtype, and adverse clinical outcome. According to molecular features, age was positively correlated with the oncogenic mutations of PIM1, MYD88, BTG2, CD79B, TET2, BTG1, CREBBP, TBL1XR1, and with the MYD88-like genetic subtype. These oncogenic mutations were involved in B-cell receptor/NF-κB signaling, B-cell differentiation, and histone acetylation based on biological functions. Older DLBCL also manifested reduction in CD4+ naïve T and CD8+ naïve T cells, and also increased recruitment of exhausted T cells and macrophages, leading to immunosuppressive tumor microenvironment. Our work thus contributes to the understanding of aging-related oncogenic mutations and tumor microenvironment alterations in lymphoma progression, and may provide new insights to mechanism-based targeted therapy in DLBCL.

Keywords: B-cell receptor; aging; diffuse large B-cell lymphoma; histone acetylation; oncogenic mutations; tumor microenvironment.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Exome Sequencing
  • Humans
  • Immediate-Early Proteins* / genetics
  • Lymphoma, Large B-Cell, Diffuse* / pathology
  • Mutation
  • Myeloid Differentiation Factor 88 / metabolism
  • Tumor Microenvironment / genetics
  • Tumor Suppressor Proteins / genetics


  • Immediate-Early Proteins
  • Myeloid Differentiation Factor 88
  • Tumor Suppressor Proteins
  • BTG2 protein, human